美国 · SEC FORM 4
Pacira BioSciences, Inc.
PCRX · Nasdaq · CIK 0001396814 · Healthcare · Drug Manufacturers—Specialty & Generic
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
21 同一窗口内观察到的 Form 4 交易行
7 sales · 14 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
Showing the six most active owners; 5 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2024-08-16 · BIGAL MARCELO.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 8,076,461
- 上期报告
- 7,561,153
- 日均成交量
- 536,467
- 回补天数
- 15.1
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2024-08-16 | Brege Laura | 买入 (P) | Common Stock | 1,000 | USD 12.81 | USD 12,810 | SEC 申报 ↗ |
| 2024-08-16 | BIGAL MARCELO | 买入 (P) | Common Stock | 1,512 | USD 13.25 | USD 20,034 | SEC 申报 ↗ |
| 2024-08-14 | YANG MICHAEL J. | 买入 (P) | Common Stock | 2,000 | USD 12.90 | USD 25,800 | SEC 申报 ↗ |
| 2024-08-12 | Lee Frank D. | 买入 (P) | Common Stock | 8,264 | USD 12.10 | USD 99,994 | SEC 申报 ↗ |
| 2024-08-12 | BIGAL MARCELO | 买入 (P) | Common Stock | 3,400 | USD 12.01 | USD 40,834 | SEC 申报 ↗ |
| 2024-08-12 | Froimson Mark | 买入 (P) | Common Stock | 1,400 | USD 11.58 | USD 16,212 | SEC 申报 ↗ |
| 2024-08-12 | BIGAL MARCELO | 买入 (P) | Common Stock | 3,400 | USD 12.01 | USD 40,834 | SEC 申报 ↗ |
| 2020-03-11 | WINSTON ROY | 买入 (P) | Common Stock | 2,500 | USD 36.50 | USD 91,250 | SEC 申报 ↗ |
Form 4 申报证据
50 transaction lines in the latest 365-day window; 497 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-08 | RIKER LAUREN | 卖出 (S) | Common Stock | 6,000 | USD 36.32 | USD 217,920 | SEC 申报 ↗ |
| 2026-10-08 | RIKER LAUREN | 期权行权/转换 (M) | Common Stock | 6,000 | USD 32.35 | USD 194,100 | SEC 申报 ↗ |
| 2026-08-17 | SLONIN JONATHAN | 卖出 (S) | Common Stock | 3,040 | USD 23.23 | USD 70,619 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-08 | RIKER LAUREN | 卖出 (S) | Common Stock | 6,000 | USD 36.32 | USD 217,920 | SEC 申报 ↗ |
| 2026-10-08 | RIKER LAUREN | 期权行权/转换 (M) | Common Stock | 6,000 | USD 32.35 | USD 194,100 | SEC 申报 ↗ |
| 2026-08-17 | SLONIN JONATHAN | 卖出 (S) | Common Stock | 3,040 | USD 23.23 | USD 70,619 | SEC 申报 ↗ |
| 2026-06-11 | RIKER LAUREN | 卖出 (S) | Common Stock | 6,115 | USD 23.50 | USD 143,702 | SEC 申报 ↗ |
| 2026-06-10 | Young Alethia | 奖励/授予 (A) | Common Stock | 6,405 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-10 | YANG MICHAEL J. | 奖励/授予 (A) | Common Stock | 6,405 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-10 | Hirawat Samit | 奖励/授予 (A) | Common Stock | 6,405 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-10 | Froimson Mark | 奖励/授予 (A) | Common Stock | 6,405 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-10 | CHRISTIE CHRISTOPHER | 奖励/授予 (A) | Common Stock | 6,405 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-10 | Brege Laura | 奖励/授予 (A) | Common Stock | 6,405 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-10 | BIGAL MARCELO | 奖励/授予 (A) | Common Stock | 6,405 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-04 | WILLIAMS KRISTEN | 卖出 (S) | Common Stock | 10,259 | USD 22.27 | USD 228,468 | SEC 申报 ↗ |
| 2026-06-03 | WILLIAMS KRISTEN | 代扣税 (F) | Common Stock | 8,528 | USD 22.32 | USD 190,345 | SEC 申报 ↗ |
| 2026-06-03 | SLONIN JONATHAN | 代扣税 (F) | Common Stock | 4,728 | USD 22.32 | USD 105,529 | SEC 申报 ↗ |
| 2026-06-03 | RIKER LAUREN | 代扣税 (F) | Common Stock | 3,187 | USD 22.32 | USD 71,134 | SEC 申报 ↗ |
| 2026-04-23 | Cross Shawn | 卖出 (S) | Common Stock | 12,941 | USD 25.16 | USD 325,596 | SEC 申报 ↗ |
| 2026-04-23 | Cross Shawn | 期权行权/转换 (M) | Common Stock | 12,941 | USD 16.45 | USD 212,879 | SEC 申报 ↗ |
| 2026-04-22 | Cross Shawn | 卖出 (S) | Common Stock | 1,500 | USD 25.01 | USD 37,515 | SEC 申报 ↗ |
| 2026-04-22 | Cross Shawn | 期权行权/转换 (M) | Common Stock | 1,500 | USD 16.45 | USD 24,675 | SEC 申报 ↗ |
| 2026-04-21 | Cross Shawn | 卖出 (S) | Common Stock | 2,845 | USD 25.01 | USD 71,153 | SEC 申报 ↗ |
| 2026-04-21 | Cross Shawn | 期权行权/转换 (M) | Common Stock | 2,845 | USD 16.45 | USD 46,800 | SEC 申报 ↗ |
| 2026-04-20 | Cross Shawn | 卖出 (S) | Common Stock | 7,714 | USD 25.14 | USD 193,930 | SEC 申报 ↗ |
| 2026-04-20 | Cross Shawn | 期权行权/转换 (M) | Common Stock | 7,714 | USD 16.45 | USD 126,895 | SEC 申报 ↗ |
| 2026-03-17 | SLONIN JONATHAN | 卖出 (S) | Common Stock | 3,261 | USD 22.82 | USD 74,416 | SEC 申报 ↗ |
| 2026-03-17 | Froimson Mark | 卖出 (S) | Common Stock | 500 | USD 21.81 | USD 10,905 | SEC 申报 ↗ |
| 2026-02-11 | WILLIAMS KRISTEN | 奖励/授予 (A) | Common Stock | 54,546 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-11 | Teehan Brendan | 奖励/授予 (A) | Common Stock | 51,714 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-11 | SLONIN JONATHAN | 奖励/授予 (A) | Common Stock | 54,546 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-11 | RIKER LAUREN | 奖励/授予 (A) | Common Stock | 19,273 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-11 | Lee Frank D. | 奖励/授予 (A) | Common Stock | 261,818 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | PCRX |
| CIK | 0001396814 |
| 行业 | Healthcare |
| 细分行业 | Drug Manufacturers—Specialty & Generic Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 497 transaction lines from 2020-01-15 to 2026-10-08 8 P purchase lines · 231 S sale lines · 258 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.